Glenmark Pharmaceuticals Inc. USA has received FDA approval for the oral route rosuvastatin calcium ANDA, entering the generic market for the highly prescribed cholesterol-lowering medication. This litigation-free approval is expected to intensify price competition against the brand leader AstraZeneca, potentially pressuring the overall market dynamics of the statin class.